Search
Boehringer_Ingelheim_Summary_Report_2015.pdf
Boehringer_Ingelheim_Unternehmensbericht_2015.pdf
Boehringer_Ingelheim_Biosimilars.pdf
Boehringer_Ingelheim_consolidated_companies_2015.pdf
Boehringer_Ingelheim_Annual_Report_2015.pdf
Boehringer_Ingelheim_company_profile_2015.pdf
Boehringer_Ingelheim_Corporate_Factsheet.pdf
Boehringer_Ingelheim_Kurzbericht_2016.pdf
Boehringer_Ingelheim_Summary_Report_2016.pdf
Boehringer_Ingelheim_Annual_Report_2016.pdf
Boehringer_Ingelheim_Unternehmensbericht_2016.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
Boehringer_Ingelheim_Consolidated_Companies_2016.pdf
FSA-Transparenzbericht Boehringer Ingelheim 2016.pdf
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim
Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Global Network | Bioxcellence | Boehringer Ingelheim
Our network of manufacturing facilities spans the globe, from Fremont, in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China
Media & News | Bioxcellence | Boehringer Ingelheim
Stay updated with BioXcellence Media & News. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
Boehringer Ingelheim - Life Forward
Learn how we change life for the better for people and animals.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis